Toshimitsu Fujii

Efficacy and safety of upadacitinib for Crohn’s disease in patients in East Asia: a post hoc analysis of randomized phase 3 studies

Minhu Chen, Xiang Gao, Kenji Watanabe, Toshimitsu Fujii et autres

cn, jp, kr, tw, us, it (code pays fourni par la source)

Real-world data on the effectiveness of risankizumab as induction therapy for ustekinumab-refractory ulcerative colitis

Ryo Morikawa, Toshimitsu Fujii, Akiko Tamura, Ami Kawamoto et autres

Efficacy and safety of ozanimod in Japanese patients with moderately to severely active ulcerative colitis naive to immunomodulators or advanced therapies: post hoc analysis of the phase 2/3 J-True North study

Tadakazu Hisamatsu, Toshimitsu Fujii, Hiroshi Nakase, Katsuyoshi Matsuoka et autres

jp (code pays fourni par la source)

Case Report of a Rapidly Progressive Indolent T‐Cell Lymphoma of the Gastrointestinal Tract

Keitaro Shibuya, Akiko Tamura, Daiki Yafuso, Ami Kawamoto et autres

jp (code pays fourni par la source)

P0326 Disease Behaviour Progression and Associated Factors in Crohn’s Disease Patients: the Nationwide Inception Cohort Study of Crohn’s Disease (iCREST-CD)

K Matsuoka, Toshimitsu Fujii, R Okamoto, Akihiro Yamada et autres

jp, br (code pays fourni par la source)

Data-Driven Subphenotyping Uncovers Ulcerative Colitis Subtype With High Risk for Relapse in Japan

Yohei Mikami, H Yamazaki, Tadakazu Hisamatsu, Masakazu Nagahori et autres

us, jp (code pays fourni par la source)

Diagnostic Performance of Fecal Biomarkers and Their Correlation with Endoscopic Severity in Immune Checkpoint Inhibitor-Related Colitis

Ryo Morikawa, Toshimitsu Fujii, Akiko Tamura, Ami Kawamoto et autres

jp (code pays fourni par la source)

Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: a post hoc analysis of safety and effectiveness in older (≥65 years) and younger (<65 years) patients

Katsuyoshi Matsuoka, Takayuki Yamamoto, Minoru Matsuura, Toshimitsu Fujii et autres

jp (code pays fourni par la source)

Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn’s Disease

Marla C. Dubinsky, Geert D’Haens, Olivier Dewit, Pascal Juillerat et autres

us, nl, be, ch, ca, jp (code pays fourni par la source)

Once-Daily Oral Ozanimod for Japanese Patients With Ulcerative Colitis: Results From the Phase 2/3 J-True North Study

Hiroshi Nakase, Toshimitsu Fujii, Tadakazu Hisamatsu, Yasuo Suzuki et autres

jp, us (code pays fourni par la source)

A Rare Case of Immune‐related Adverse Events Localized to the Small Intestine

Ryo Morikawa, Ryosuke Kanaya, Hiromichi Shimizu, Masayoshi Fukuda et autres

jp, us, at (code pays fourni par la source)

Sustained corticosteroid-sparing effects of upadacitinib maintenance therapy in patients with moderate-to-severe crohn’s disease: 2-year results from the U-ENDURE long-term extension study

Irina Blumenstein, Vipul Jairath, Marla C. Dubinsky, Luc Biedermann et autres

de, ca, us, ch, jp (code pays fourni par la source)